Emergent BioSolutions completes sales, deliveries of BioThrax to allied international governments

Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has completed separate international sales and deliveries of BioThrax^® (Anthrax Vaccine Adsorbed) to governments of several allied nations. The company's international sales efforts have resulted in these sales of an undisclosed number of BioThrax doses for aggregate revenue of approximately $2.3 million in the second quarter.

“As the maker of the only U.S. FDA-licensed anthrax vaccine, and in line with our corporate mission to protect life, we are honored to support such biopreparedness efforts of allied international governments.”

"Emergent recognizes that governments play a key role in protecting citizens against the growing threat of bioterrorism," said Allen Shofe, senior vice president public affairs of Emergent BioSolutions. "As the maker of the only U.S. FDA-licensed anthrax vaccine, and in line with our corporate mission to protect life, we are honored to support such biopreparedness efforts of allied international governments."